The EIF2AK3 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the 786-O human renal cell carcinoma line, engineered for disruption of the EIF2AK3 gene encoding PERK. This loss-of-function model eliminates PERK kinase activity, enabling dissection of its roles in ER stress signaling without single-cell cloning, accommodating population heterogeneity.
The 786-O cell line, established from a primary clear cell renal cell carcinoma, serves as a widely used model for renal cancer research. These adherent epithelial cells exhibit hallmarks of ccRCC, including VHL inactivation, and are employed to study tumorigenesis, metastasis, and response to targeted agents such as sorafenib and sunitinib.
PERK (EIF2AK3) is an ER-resident transmembrane serine/threonine kinase that functions as a key sensor in the unfolded protein response (UPR). In unstressed cells, PERK is maintained in an inactive state through binding to the chaperone BiP/GRP78. Accumulation of misfolded proteins causes BiP dissociation, leading to PERK dimerization, autophosphorylation, and activation. Activated PERK phosphorylates eIF2?? at Ser51, which attenuates global mRNA translation while allowing selective translation of transcripts such as ATF4. ATF4 transactivates downstream targets including CHOP/DDIT3, GADD34, and NRF2, thereby dictating outcomes of stress adaptation or apoptosis. PERK signaling intersects with the IRE1?? and ATF6 UPR pathways and indirectly modulates mTOR signaling and the integrated stress response (ISR).
In the context of 786-O renal carcinoma cells, PERK may be critical for adapting to the harsh tumor microenvironment characterized by hypoxia and nutrient deprivation, as well as for developing resistance to therapies such as sorafenib and sunitinib. Disruption of EIF2AK3 enables systematic assessment of PERK-dependent effects on cell viability, apoptosis, autophagy, and invasive potential following treatment with ER stressors (e.g., tunicamycin, thapsigargin) or chemotherapeutics. This model is particularly valuable for exploring synthetic lethal interactions and for differentiating the contributions of the PERK branch from other UPR sensors in renal cancer progression.
Key research applications encompass detailed analysis of UPR signaling, drug sensitivity profiling, synthetic lethality screens, and functional assays for metastasis and invasion. Experimental approaches include western blotting for PERK, phospho-eIF2??, ATF4, and CHOP; RT-qPCR for UPR target genes; ER stress reporter assays; cell viability and apoptosis assays under tunicamycin/thapsigargin challenge; migration and invasion assays; co-immunoprecipitation to detect PERK-containing complexes; colony formation assays; drug sensitivity testing against sorafenib and sunitinib; and flow cytometric cell cycle analysis. The EIF2AK3 Knockout 786-O Polyclonal Cells thus provide a versatile tool for unraveling PERK-mediated mechanisms in renal cell carcinoma. For further technical information or custom requests, please contact Ascent Research.
